Drug intelligence / Profile preview

LA1011

Development stage: Preclinical
Lead developer: LipidArt Research and Development
Modality: Small Molecules
Administration: Oral

Overview

LA1011 is a small molecule neuroprotective drug candidate developed by LipidArt. It is designed to modulate Heat Shock Protein 90 (HSP90), thereby strengthening the cellular stress response. The drug is being investigated for the treatment of neurodegenerative diseases, including dementia and cognitive impairment. Preclinical studies have evaluated its safety and efficacy via oral administration in rat models, focusing on its ability to protect neurons from stress-induced damage. LA1011 was developed from LipidArt's patented molecule library and is currently in the preclinical stage of development.

Targets

HSP90AB1 (Heat shock protein HSP 90-beta)HSP90AA1 (Heat shock protein HSP90-alpha)

Beyond the preview

Go deeper on LA1011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LA1011.

Explore the full profile